Aon plc, the global professional services firm, recently conducted the first-ever large-scale analysis of GLP-1 treatments focused on workforce impact, studying more than 50 million commercial claims over a span of three years
Cancer Res 66 : 1129811304 Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
The study looked at nearly 140,000 patients with type 2 diabetes from 2020 to 2023
PBG: Postprandial blood glucose) Bioanalytical challenges in the development of GLP-1 RAs Pharmacokinetic studies are critical in the development of GLP-1 analogues
Your digestive tolerance depends more on underlying conditionssuch as irritable bowel syndrome, history of pancreatitis, or post-surgical adhesionsthan on gallbladder status alone
These investigations help researchers examine how metabolic signaling pathways influence energy substrate utilization, lipid mobilization, and tissue-specific metabolic responses